Anticancer alkaloids from trees: Development into drugs

Pharmacognosy Reviews

Volumn 10, Issue 20, 2016, Pages 90-99

  Isah, Tasiu ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Alkaloids; camptothecin; cancer; natural products; taxol; trees

Indexed keywords

ACRONINE; ANTINEOPLASTIC ALKALOID; BENZOPHENANTHRIDINE DERIVATIVE; CAMPTOTHECIN; CHELERYTHRINE; CHELIDONINE; ELLIPTICINE; HARRINGTONINE; MATRINE; PACLITAXEL; ROHITUKINE; THALICARPINE; UNCLASSIFIED DRUG; USAMBARENSINE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; DRUG ISOLATION; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; MALIGNANT NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TREE;

EID: 85001097609     PISSN: 09737847     EISSN: 09762787     Source Type: Journal    
DOI: 10.4103/0973-7847.194047     Document Type: Review

References (189)

1. WHO. The Top 10 Causes of Death Fact Sheet No. 310; 2014a. Available from: http://www. who. int/mediacentre/factsheets/fs297/en. [Last retrieved on 2014 Jun 10].
2. WHO. World Cancer Report 2014. Ch. 1. 1. WHO; 2014b. Available from:. [Last retreaved on 2015 Jun 11].
3. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA. Plant antitumor agents I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata. J Am Chem Soc 1966;88:3888-90. [doi: 10. 1021/ja00968a057].
4. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-7.
5. Cragg GM, Newman DJ. Nature: A vital source of leads for anticancer drug development. Phytochem Rev 2009;8:313-31.
6. Levinson HZ. The defensive role of alkaloid in insects and plants. Experimentia 1976;32:408-11.
7. Orekhov AP. Chemistry of alkaloids (2nd ed.). Academy of Science USSR, Moscow; 1955. p. 12.
8. Raffauf RF. Plant Alkaloids: A Guide to Their Discovery and Distribution. New York: Hawk Worth Press, Inc. ; 1996. p. 298.
9. Manfred H. Alkaloids: Nature's Curse or Blessing? Wiley-VCH Verlag, Germany; 2003. p. 24-6. doi:10. 1002/anie. 200385928.
10. Tadeusz A. Alkaloids-Secrets of Life. Amsterdam: Elsevier; 2007.
11. Lee KH. Anticancer drug design based on plant-derived natural products. J Biomed Sci 1999;6:236-50.
12. Dholwani KK, Saluja AK, Gupta AR, Shah DR. A review on plant-derived natural products and their analogs with anti-tumor activity. Indian J Pharmacol 2008;40:49-58.
13. Mollov N, Dutschewska H, Siljanovska K, Stojcev S. Cytotoxic effect of alkaloids from Thalictrum minus Sp. elatum and their derivatives. Dokl Bolgar Acad Nauk 1968;21:605-8.
14. Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol 1981;91(2 Pt 1):479-87.
15. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-8.
16. Faddeeva MD, Beliaeva TN. Sanguinarine and ellipticine cytotoxic alkaloids isolated from well-known antitumor plants. Intracellular targets of their action. Tsitologiia 1997;39:181-208.
17. Vidensek N, Lim P, Campbell A, Carlson C. Taxol content in bark, wood, root, leaf, twig, and seedling from several Taxus species. J Nat Prod 1990;53:1609-10.
18. Wheeler NC, Jech K, Masters S, Brobst SW, Alvarado AB, Hoover AJ, et al. Effects of genetic, epigenetic, and environmental factors on taxol content in Taxus brevifolia and related species. J Nat Prod 1992;55:432-40.
19. Padmanabha BV, Chandrashekar M, Ramesha BT, Hombe Gowda HC, Gunaga RP, Suhas S, et al. Patterns of accumulation of camptothecin, an anticancer alkaloid in N. nimmoniana Graham, in the Western Ghats, India: Implications for identifying high-yielding sources of the alkaloid. Curr Sci 2006;90:95-100.
20. McChesney JD, Venkataraman SK, Henri JT. Plant natural products: Back to the future or into extinction? Phytochemistry 2007;68:2015-22.
21. Nobili S, Lippi D, Witort E, Donnini M, Bausi L, Mini E, et al. Natural compounds for cancer treatment and prevention. Pharmacol Res 2009;59:365-78.
22. Hait WN. Anticancer drug development: The grand challenges. Nat Rev Drug Discov 2010;9:253-4.
23. Kantarjian HM, O'Brien S, Cortes J. Homoharringtonine/omacetaxine mepesuccinate: The long and winding road to food and drug administration approval. Clin Lymphoma Myeloma Leuk 2013;13:530-3.
24. Chabner BA, Roberts TG. Chemotherapy and the war on cancer. Nat Rev Cancer 2005;5:65-72.
25. DeVita VT Jr., Chu E. A history of cancer chemotherapy. Cancer Res 2008;68:8643-53.
26. Oberlies NH, Kroll DJ. Camptothecin and taxol: Historic achievements in natural products research. J Nat Prod 2004;67:129-35.
27. Isah T. Natural sources of taxol. Br J Pharm Res 2015;6:214-27.
28. Nemeth-Kiss V, Forgacs E, Cserhatti T, Schmidt G. Taxol content of various Taxus species in Hungary. J Pharm Biomed Anal 1996;14:997-1001.
29. Zhou X, Zhu H, Liu L, Lin J, Tang K. A review: Recent advances and future prospects of taxol-producing endophytic fungi. Appl Microbiol Biotechnol 2010;86:1707-17.
30. Das B, Rao SP, Kashinatham A. Taxol content in the storage samples of the needles of Himalayan Taxus baccata and their extracts. Planta Med 1998;64:96.
31. Wianowska D, Hajnos ML, Dawidowicz AL, Oniszczukc A, Waksmundzka-Hajnosc M, Głowniak K, et al. Extraction methods of 10-deacetylbaccatin III, paclitaxel, and cephalomannine from Taxus baccata L. twigs: A comparison. J Liq Chromatogr Relat Technol 2014;32:589-601.
32. Wall ME, Wani MC. Camptothecin and taxol: From discovery to clinic. J Ethnopharmacol 1996;51:239-53.
33. Saville MW, Lietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, et al. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 1995;346:26-8.
34. Humphreys A, Scussa F. Med Ad News. May, 2001. p. 1.
35. Löwe J, Li H, Downing KH, Nogales E. Refined structure of alpha beta-tubulin at 3. 5 P resolution. J Mol Biol 2001;313:1045-57.
36. Bharadwaj R, Yu H. The spindle checkpoint, aneuploidy, and cancer. Oncogene 2004;23:2016-27.
37. Brito DA, Yang Z, Rieder CL. Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied. J Cell Biol 2008;182:623-9.
38. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
39. Ganguly A, Yang H, Cabral F. Paclitaxel-dependent cell lines reveal a novel drug activity Mol Cancer Ther 2010;9:2914-23.
40. Holton RA, Somoza C, Kim HB, Liang F, Biediger RJ, Boatman PD, et al. First total synthesis of taxol functionalization of the B ring. J Am Chem Soc 1994;116:1597-8.
41. Nicolau KC, Yang Z, Liu JJ. Total synthesis of taxol. Nat Biotechnol 1994;367:630-4.
42. Hartwell JL. Types of anticancer agents isolated from plants. Cancer Treat Rep 1976;60:1031-67.
43. Jean-Noel D, Greene AE. A highly efficient, practical approach to natural taxol. J Am Chem Soc 1988;110:5917-9.
44. Holton RA, Biediger RJ, Boatman PD. Semi synthesis of taxol and taxotere. In: Suffness M, editor. Taxol: Science and Application. Boca Raton, FL, USA: CRC; 1995. p. 97-121.
45. Goodman J, Walsh V. The Story of Taxol: Nature and Politics in the Pursuit of Anti-Cancer Drug. British Med J 323;7304:115.
46. Yared JA, Tkaczuk KH. Update on taxane development: New analogs and new formulations. Drug Des Devel Ther 2012;6:371-84.
47. Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. J Ethnopharmacol 2005;100:72-9.
48. Amna T, Puri SC, Verma V, Sharma JP, Khajuria RK, Musarrat J, et al. Bioreactor studies on the endophytic fungus Entrophospora infrequens for the production of an anticancer alkaloid camptothecin. Can J Microbiol 2006;52:189-96.
49. Wall ME, Wani MC. Camptothecin and taxol: Discovery to clinic-Thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1995;55:753-60.
50. Gerrits CJ, de Jonge MJ, Schellens JH, Stoter G, Verweij J. Topoisomerase I inhibitors: The relevance of prolonged exposure for present clinical development. Br J Cancer 1997;76:952-62.
51. Wani MC, Wall ME. Plant antitumor agents II The structure of two new alkaloids from Camptotheca acuminate. J Org Chem 1969;51:1364-7.
52. Wall ME. Alkaloids with antitumor activity. In: Mothes K, Schrelber K, Schutte HR, editors. International Symposium on Biochemistry and Physiology of the Alkaloids. Berlin: Academic-Verlag; 1969. p. 77-87.
53. Wani MC, Ronman PE, Lindley JT, Wall ME. Plant antitumor agents 18. Synthesis and biological activity of camptothecin analogues. J Med Chem 1980;23:554-60.
54. Gottlieb JA, Luce JK. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 1972;56:103-5.
55. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 1972;56:515-21.
56. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972;56:95-101.
57. Bin X. New results in pharmacologic research of some anticancer agents. In: Burns JJ, Tsuchitani PJ, editors. US/China Pharmacology Symposium. Washington, DC: National Academy of Sciences; 1980. p. 151-88.
58. Rothenberg ML. Topoisomerase I inhibitors: Review and update. Ann Oncol 1997;8:837-55.
59. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002;8:641-61.
60. Harmon AD, Weiss U, Silverton JV. The structure of rohitukine the main alkaloid of Amoora rohituka (Syn) Aphanamixis polystachya (Meliaceae). Tetrahedron Lett 1979;20:721-4.
61. Naik R, Ramachandra G, Kattige SL, Bhat SV, Alreja B, de Souza NJ, Rupp RH, et al. An anti-inflammatory and immunomodulatory piperidinyl benzopyranone from Dysoxylum binectariferum: Isolation, structure and total synthesis. Tetrahedron 1988;44:2081-6.
62. Houghton PJ, Hairong Y. Further Chromone Alkaloids from Schumanniophyton magnificum. Planta Med 1987;53:262-4.
63. Houghton PJ, Woldermariam TZ. High performance liquid chromatographic analysis of chromane alkaloids from Schumanniophyton species. Phytochem Anal 1993;4:9-13.
64. Mohana KP, Zuehlke S, Priti V, Ramesha BT, Shweta S, Ravikanth G, et al. Fusarium proliferatum, an endophytic fungus from Dysoxylum binectariferum Hookf, produces rohitukine, a chromane alkaloid possessing anti-cancer activity. Antonie van Leeuwenhoek 2012;101:323-9.
65. Kumara PM, Soujanya KN, Ravikanth G, Vasudeva R, Ganeshaiah KN, Shaanker RU. Rohitukine, a chromone alkaloid and a precursor of flavopiridol, is produced by endophytic fungi isolated from Dysoxylum binectariferum Hook. f and Amoora rohituka (Roxb). Wight and Arn. Phytomedicine 2014;21:541-6.
66. Houghton PJ. New chromone alkaloids from the stem bark of Schumanniophyton magnificum. Planta Med 1988;54:239-42.
67. Yang DH, Cai SQ, Zhao YY, Liang H. A new alkaloid from Dysoxylum binectariferum. J Asian Nat Prod Res 2004;6:233-6.
68. Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pestell R, et al. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 1999;59:4634-41.
69. Varshney S, Shankar K, Beg M, Balaramnavar VM, Mishra SK, Jagdale P, et al. Rohitukine inhibits in vitro adipogenesis arresting mitotic clonal expansion and improves dyslipidemia in vivo. J Lipid Res 2014;55:1019-32.
70. Keshri G, Oberoi RM, Lakshmi V, Pandey K, Singh MM. Contraceptive and hormonal properties of the stem bark of Dysoxylum binectariferum in rat and docking analysis of rohitukine, the alkaloid isolated from active chloroform soluble fraction. Contraception 2007;76:400-7.
71. Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Fitch TR, Fenton RG, et al. Flavopiridol in patients with relapsed or refractory multiple myeloma: A phase 2 trial with clinical and pharmacodynamic end-points. Haematologica 2006;91:390-3.
72. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996;56:2973-8.
73. Brown JR. Chronic lymphocytic leukemia: A niche for flavopiridol? Clin Cancer Res 2005;11:3971-3.
74. Christian BA, Grever MR, Byrd JC, Lin TS. Flavopiridol in the treatment of chronic lymphocytic leukemia. Curr Opin Oncol 2007;19:573-8.
75. Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 1992;84:1736-40.
76. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000;92:376-87.
77. Senderowicz AM. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms. Cancer Chemother Pharmacol 2003;52:61-73.
78. Schmerwitz UK, Sass G, Khandoga AG, Joore J, Mayer BA, Berberich N, et al. Flavopiridol protects against inflammation by attenuating leukocyte-endothelial interaction via inhibition of cyclin-dependent kinase 9. Arterioscler Thromb Vasc Biol 2011;3:280-8.
79. Perkins KJ, Lusic M, Mitar I, Giacca M, Proudfoot NJ. Transcription-dependent gene looping of the HIV-1 provirus is dictated by recognition of pre-mRNA processing signals. Mol Cell 2008;29:56-68.
80. Biglione S, Byers SA, Price JP, Nguyen VT, Bensaude O, Price DH, et al. Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. Retrovirology 2007;4:47.
81. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998;16:2986-99.
82. Whitlock JA, Krailo M, Reid JM, Ruben SL, Ames MM, Owen W, et al. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol 2005;23:9179-86.
83. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, et al. Pharmacologically derived schedule of flavopiridol has significant efficacy in refractory, genetically high-risk chronic lymphocytic leukemia (CLL). J Clin Oncol 2006;24:6516.
84. Bible KC, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration. Cancer Res 1997;57:3375-80.
85. Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D, Vokes EE. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago phase II consortium study. J Clin Oncol 2000;18:371-5.
86. Karp JE, Smith BD, Levis MJ, Gore SD, Greer J, Hattenburg C, et al. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: A phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res 2007;13(15 Pt 1):4467-73.
87. Joshi KS, Rathos MJ, Joshi RD, Sivakumar M, Mascarenhas M, Kamble S, et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther 2007;6:918-25.
88. Manohar SM, Rathos MJ, Sonawane V, Rao SV, Joshi KS. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription. Leuk Res 2011;35:821-30.
89. Shirsath NP, Manohar SM, Joshi KS. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines. Mol Cancer 2012;11:77.
90. Manohar SM, Padgaonkar AA, Jalota-Badhwar A, Rao SV, Joshi KS. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1a and induces G2/M arrest under hypoxia in prostate cancer cells. Prostate Cancer Prostatic Dis 2012;15:15-27.
91. Brüsselbach S, Nettelbeck DM, Sedlacek HH, Müller R. Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells. Int J Cancer 1998;77:146-52.
92. Joshi KS, Rathos MJ, Mahajan P, Wagh V, Shenoy S, Bhatia D, et al. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther 2007;6:926-34.
93. Kerr JS, Wexler RS, Mousa SA, Robinson CS, Wexler EJ, Mohamed S, et al. Novel small molecule alpha v integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors. Anticancer Res 1999;19:959-68.
94. Paudler WW, Kerley GI, McKay J. The alkaloids of Cephalotaxus drupacea and C fortune J Org Chem 1963;28:2194-7
95. Huang L, Xue Z. Cephalotaxus alkaloids. Alkaloids 1984;23:157-226.
96. Powell RG, Smith CR. Structure of cephalotaxine and related alkaloids. Tetrahedron Lett 1969;46:4081-4.
97. Powell RG, Weislede D, Smith CR. Antitumor alkaloids from Cephalotaxus harringtonia: Structure and activity. J Pharm Sci 1972;61:1227-30.
98. Eckelbargerb JD, Wilmota JT, Epperson MT. Synthesis of antiproliferative cephalotaxus esters and Their evaluation against several human hematopoietic and solid tumor cell lines: Uncovering differential susceptibilities to multidrug resistance. Chemistry 2008;14:4293-306.
99. Li YH, Guo SF, Zhou FY, Zhang HL. Combined harringtonine or homoharringtonine chemotherapy for acute non-lymphocytic leukemia in 25 children. Chin Med J 1983;96(4):303-5.
100. Grem JL, Cheson BD, King SA, Leyland-Jones B, Suffness M. Cephalotaxine esters: Anti-leukemic advance or therapeutic failure? J Natl Cancer Inst 1988;80:1095-103.
101. Kantarjian HM, Talpaz M, Santini V, Murgo A, Cheson B, O'Brien SM. Homoharringtonine history, current research, and future directions. Cancer 2001;92:1591-605.
102. Zhejiang University News, Chinese Original Homoharringtonine (HHT) Therapy Significantly Increases the Survival Rate of Leukemia Patients. Available from: http://www. zjueducn/c165055/content2304737html. [Last retrieved on 2013 Jul 24].
103. Lü S, Wang J. Homoharringtonine and omacetaxine for myeloid hematological malignancies. J Hematol Oncol 2014;7:2.
104. O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995;86:3322-6.
105. O'Brien S, Kantarjian H, Koller C, Feldman E, Beran M, Andreeff M, et al. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood 1999;93:4149-53.
106. Kantarjian HM, Talpaz M, Smith TL, Cortes J, Giles FJ, Rios MB, et al. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol 2000;18:3513-21.
107. Kantarjian H, O'Brien S, Cortes J. Homoharringtonine/Omacetaxine: The Little Drug that Could-The Asco Post. NY, USA: Harborside Press (HSP) News Service, LLC37 Main Street, Cold Spring Harbor; 2013a. Available from: http://www. ascopost. com/issues/april-15-2013/homoharringtonineomacetaxine-the-little-drug-that-could/]. [Last retreaved on 2013 Aug 26].
108. Guo AX, Huang SL, Wang QE. HATP chemotherapy combined with Chinese traditional medications in treating acute promyelocytic leukemia. Zhonghua Nei Ke Za Zhi 1993;32:470-2.
109. Huang MT. Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol Pharmacol 1975;11:511-9.
110. Zhou DC, Zittoun R, Marie JP. Homoharringtonine: An effective new natural product in cancer chemotherapy. Bull Cancer 1995;82:987-95.
111. Robin J, Dhal R, Dujardin G, Girodierb L, Mevellecb L, Poutot S. The first semi-synthesis of enantiopure homoharringtonine via anhydro homoharringtonine from a preformed chiral acyl moiety. Tetrahedron Lett 1999;40:2931-4.
112. Marin D, Kaeda JS, Andreasson C, Saunders SM, Bua M, Olavarria E, et al. Phase I/II trial of adding semisynthetic homoharringtonine in CML patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 2005;103:1850-5.
113. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, et al. Phase I/II study of subcutaneous homoharringtonine in patients with CML, who have failed prior therapy. Cancer 2007;109:248-55.
114. Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 2012;120:2573-80.
115. Hughes GK, Lahey FN, Price JR, Webb LJ. Alkaloids of the Australian Rutaceae. Nature 1948;162:223-4.
116. Macdonald PL, Robertson AV. The structure of acronycine. Aust J Chem 1966;19:275-81.
117. Skaltsounis AL, Tillequin F, Koch M. Plants of new caledonia part Lxxxiii alkaloids from the leaves and stems of Melicope leptococca. J Nat Prod 1983;465:732-5.
118. Mitaku S, Skaltsounis AL, Tillequin F, Koch M, Pusset J, Chauviere G. Alcaloides de Sarcomelicope glauca. J Nat Prod 1986;49:1091-5.
119. Mitaku S, Skaltsounis AL, Tillequin F, Koch M, Pusset J. Plants from New Caledonia. Alkaloids from Sarcomelicope dogniensis Hartley stem bark. Ann Pharm Fr 1989;47:149-56.
120. Beck JR, Kwok R, Booher RN, Brown AC, Patterson LE, Pranc P, et al. Synthesis of acronycine. J Am Chem Soc 1968;90:4706-10.
121. Tillequin F. Alkaloids in the genus Sarcomelicope. Recent Res Dev Phytochem 1997;1:675-87.
122. Belmont P, Bosson J, Godet T, Tiano M. Acridine and acridone derivatives, anticancer properties and synthetic methods: Where are we now? Anticancer Agents Med Chem 2007;7:139-69.
123. Fujiwara M, Okamoto M, Okamoto M, Watanabe M, Machida H, Shigeta S, et al. Acridone derivatives are selective inhibitors of HIV-1 replication in chronically infected cells. Antiviral Res 1999;43:189-99.
124. Demeunynck M, Charmantray F, Martelli A. Interest of acridine derivatives in the anticancer chemotherapy. Curr Pharm Des 2001;7:1703-24.
125. Bernardino AM, Castro HC, Frugulhetti IC, Loureiro NI, Azevedo AR, Pinheiro LC, et al. SAR of a series of anti-HSV-1 acridone derivatives, and a rational acridone-based design of a new anti-HSV-1 3H-benzo[b] pyrazolo[3,4-h]-1,6-naphthyridine series. Bioorg Med Chem 2008;16:313-21.
126. Sepúlveda CS, Fascio ML, García CC, D'Accorso NB, Damonte EB. Acridones as antiviral agents: Synthesis, chemical and biological properties. Curr Med Chem 2013;20:2402-14.
127. Scarffe JH, Beaumont AR, Crowther D. Phase I-II evaluation of acronine in patients with multiple myeloma. Cancer Treat Rep 1983;67:93-4.
128. Kuo YH, King ML. Antitumor drugs from the secondary metabolites of higher plants. In: Tringali C, editor. Bioactive Compounds from Natural Sources: Isolation, Characterization and Biological properties. London and New York: Taylor and Francis; 2001. p. 221-4.
129. Tan P, Auersperg N. Effects of the antineoplastic alkaloid acronycine on the ultrastructure and growth patterns of cultured cells. Cancer Res 1973;33:2320-9.
130. Shieh HL, Pezzuto JM, Cordell GA. Evaluation of the cytotoxic mechanisms mediated by the broad-spectrum antitumor alkaloid acronycine and selected semisynthetic derivatives. Chem Biol Interact 1992;81:35-55.
131. Svoboda GH. Alkaloids of Acronychia baueri (Bauerella australiana)-Extraction of the alkaloids and studies of structure-activity-relationships. Lloydia 1966;29:206-24.
132. Svoboda GH, Poore GA, Simpson PJ, Boder GB. Alkaloids of Acronychia baueri Schott I. Isolation of the alkaloids and a study of the antitumor and other biological properties of acronycine. J Pharm Sci 1966;55:758-68.
133. Gerzon K, Svoboda GH. Acridone alkaloids: Experimental antitumor activity of acronycine In: Brossi A, editor. The Alkaloids. Vol. 21. New York: Academic Press; 1983. p. 1-28.
134. Tillequin F. Rutaceous alkaloids as models for the design of novel antitumor drugs. Phytochem Rev 2007;6:65-79.
135. David-Cordonnier MH, Laine W, Lansiaux A, Kouach M, Briand G, Pierré A, et al. Alkylation of guanine in DNA by S23906-1, a novel potent antitumor compound derived from the plant alkaloid acronycine. Biochemistry 2002;41:9911-20.
136. Cahuzac N, Studény A, Marshall K, Versteege I, Wetenhall K, Pfeiffer B, et al. An unusual DNA binding compound, S23906, induces mitotic catastrophe in cultured human cells. Cancer Lett 2010;289:178-87.
137. Leonce S, Perez V, Lambel S, Peyroulan D, Tillequin F, Michel S, et al. Induction of cyclin E and inhibition of DNA synthesis by the novel acronycine derivative S23906-1 precede the irreversible arrest of tumor cells in S phase leading to apoptosis. Mol Pharmacol 2001;60:1383-91.
138. Kostakis I, Ghirtis K, Pouli N, Marakos P, Skaltsounis AL, Leonce S, et al. Synthesis and cytotoxic activity of 2-dialkylaminoethylamino substituted xanthenone and thioxanthenone derivatives. Farmaco 2000;55:455-60.
139. Kupchan SM, Yokoyama N. The structure, configuration and synthesis of thalicarpine, a novel dimeric aporphine-benzylisoquinoline alkaloid. J Am Chem Soc 1963;85:1361-2.
140. Tomita M, Furukawa H, Lu ST, Kupchan SM. The constitution of thalicarpine. Chem Pharm Bull (Tokyo) 1967;15:959-63.
141. Kupchan SM. Recent advances in the chemistry of tumor inhibitors of plant origin. Trans N Y Acad Sci 1970;32:85-106.
142. Broder IE, Carter SK. Thalicarpine (NSC-68075) Clinical Brochure, Drug Development. Bethesda, Md: National Cancer Institute; 1971.
143. Allen LM, Creaven PJ. Inhibition of macromolecular biosynthesis in cultured L1210 mouse leukemia cells by thalicarpine (NSC 68075). Cancer Res 1974b; 33:3112-6.
144. Allen LM, Creaven PJ. Inhibition of macromolecular biosynthesis in cultured L1210 mouse leukemia cells by thalicarpine (NSC 68075). Cancer Res 1973;33:3112-6.
145. Chen G, Zeller WJ. In vitro investigations on induction and reversal of cisplatin resistance in a rat ovarian tumor cell line. J Cancer Res Clin Oncol 1990;116:443-7.
146. Allen LM, Creaven PJ. Binding of a new antitumor agent, thalicarpine, to DNA. J Pharm Sci 1974;63:474-5.
147. Creaven PJ, Cohen MH, Selawry OS, Tejada F, Broder LE. Phase I study of thalicarpine (NAC-68075), a plant alkaloid of noval structure. Cancer Chemother Rep 1975;59:1001-6.
148. Leimert JT, Corder MP, Elliott TE, Lovett JM. An abbreviated phase II trial of thalicarpine. Cancer Treat Rep 1980;64:1389-90.
149. Goodwin S, Smith AF, Horning EC. Alkaloids of Ochrosia elliptica Labill. J Am Chem Soc 1959;81:1903-8.
150. Dalton LK, Demerac S, Elmes BC, Loder JW, Swan JM, Teitei T, et al. Synthesis of the tumor inhibitory alkaloids, ellipticine, 9-methoxyellipticine, and related pyrido [4, 3-b] carbazoles. Aust J Chem 1967;20:2715-27.
151. Miller CM, McCarthy FO. Isolation, biological activity and synthesis of the natural product ellipticine and related pyridocarbazoles. RSC Adv 2012;2:8883-918.
152. Clarysse A, Brugarolas A, Siegenthaler P, Abele R, Cavalli F, de Jager R, et al. Phase II study of 9-hydroxy-2N-methylellipticinium acetate. Eur J Cancer Clin Oncol 1984;20:243-7.
153. Sakamoto-Hojo ET, Takahashi CS, Ferrari I, Motidome M. Clastogenic effect of the plant alkaloid ellipticine on bone marrow cells of Wistar rats and on human peripheral blood lymphocytes. Mutat Res 1988;199:11-9.
154. Andrews WJ, Panova T, Normand C, Gadal O, Tikhonova IG, Panov KI. Old drug, new target: Ellipticines selectively inhibit RNA polymerase I transcription. J Biol Chem 2013;288:4567-82.
155. Stiborová M, Poljaková J, Martínková E, Borek-Dohalská L, Eckschlager T, Kizek R, et al. Ellipticine cytotoxicity to cancer cell lines-A comparative study. Interdiscip Toxicol 2011;4:98-105.
156. Auclair C. Multimodal action of antitumor agents on DNA: The ellipticine series. Arch Biochem Biophys 1987;259:1-14.
157. Suffness M, Cordell GA. Antitumor alkaloids In: Brossi A, editor. The Alkaloids. Vol. 25. New York: Academic Press; 1985. p. 178-87.
158. Paoletti C, Le Pecq JB, Dat-Xuong N, Juret P, Garnier H, Amiel JL, et al. Antitumor activity, pharmacology, and toxicity of ellipticines, ellipticinium, and 9-hydroxy derivatives: Preliminary clinical trials of 2-methyl-9-hydroxy ellipticinium (NSC 264-137). Recent Results Cancer Res 1980;74:107-23.
159. Bonjean KA, De Pauw-Gillet MC, Quetin-Leclercq J, Angenot L, Bassleer RJ. In vitro cytotoxic activity of two potential anticancer drugs isolated from Strychnos: Strychnopentamine and usambarensine. Anticancer Res 1996;16:1129-37.
160. Frédérich M, Bentires-Alj M, Tits M, Angenot L, Greimers R, Gielen J, et al. Isostrychnopentamine, an indolomonoterpenic alkaloid from Strychnos usambarensis, induces cell cycle arrest and apoptosis in human colon cancer cells. J Pharmacol Exp Ther 2003;304:1103-10.
161. Dassonneville L, Wattez N, Mahieu C, Colson P, Houssier C, Frederich M, et al. The plant alkaloid usambarensine intercalates into DNA and induces apoptosis in human HL60 leukemia cells. Anticancer Res 1999;19:5245-50.
162. Miao KL, Zhang JZ, Dong Y, Xi YF. Research progress on the chemical compounds and pharmacology of Sophra flavescens. Nat Prod Res Dev 2001;13:69-73.
163. Krishna MP, Rao KN, Sandhya S, Banji D. A review on phytochemical, ethnomedical and pharmacological studies on genus Sophora, Fabaceae. Rev Bras Farmacogn 2012;22:1145-54.
164. Zhang Y, Zhang H, Yu P, Liu Q, Liu K, Duan H, et al. Effects of matrine against the growth of human lung cancer and hepatoma cells as well as lung cancer cell migration. Cytotechnology 2009;59:191-200.
165. Xiangru X, Jikai J. Recent progress in the anticancer bioactivity study of Sophora flavescens and its alkaloids. Chin J Int Tradit Chin West Med 1998;4:235-9.
166. Wang Y, Peng C, Zhang G, Liu Y, Li H, Shan J, et al. Study on invasion and metastasis related factors in the differentiation of SMMC-7721 cells induced by matrine. Zhong Yao Cai 2003;26:566-9.
167. Luo C, Zhong HJ, Zhu LM, Wu XG, Ying JE, Wang XH, et al. Inhibition of matrine against gastric cancer cell line MNK45 growth and its anti-tumor mechanism. Mol Biol Rep 2012;39:5459-64.
168. Zhang JQ, Li YM, Liu T, He WT, Chen YT, Chen XH, et al. Antitumor effect of matrine in human hepatoma G2 cells by inducing apoptosis and autophagy. World J Gastroenterol 2010;16:4281-90.
169. Ma L, Wen S, Zhan Y, He Y, Liu X, Jiang J. Anticancer effects of the Chinese medicine matrine on murine hepatocellular carcinoma cells. Planta Med 2008;74:245-51.
170. Zhang L, Wang T, Wen X, Wei Y, Peng X, Li H, Wei L. Effect of matrine on HeLa cell adhesion and migration. Eur J Pharmacol 2007;563:69-76.
171. Govindachari TR, Viswanathan N. Alkaloids of Mappia foetida. Phytochemistry 1972;11:3529-31.
172. Li S, Yi Y, Wang Y, Zhang Z, Beasley RS. Camptothecin accumulation and variations in camptotheca. Planta Med 2002;68:1010-6.
173. Gunasekera SP, Badawi MM, Cordell GA, Farnsworth NR, Chitnis M. Plant anticancer agents X. Isolation of camptothecin and 9-methoxycamptothecin from Ervatamia heyneana. J Nat Prod 1979;42:475-7.
174. Arisawa M, Gunasekera SP, Cordell GA, Farnsworth NR. Plant anticancer agents XXI. Constituents of Merrilliodendron megacarpum. Planta Med 1981;43:404-7.
175. Dai JR, Cardellina JH, Boyd MR. 20-Oβ-Glucopyranosyl camptothecin from Mostuea brunonis: a potential camptothecin prodrug with improved solubility. J Nat Prod 1999;62:1427-9.
176. Zhou BN, Hoch JM, Johnson RK, Mattern MR, Eng WK, Ma J, et al. Use of COMPARE analysis to discover new natural product drugs: Isolation of camptothecin and 9-methoxycamptothecin from a new source. J Nat Prod 2000;63:1273-6.
177. Ramesha BT, Suma HK, Senthilkumar U, Priti V, Ravikanth G, Vasudeva R, et al. New plant sources of the anti-cancer alkaloid, camptothecine from the Icacinaceae taxa, India. Phytomedicine 2013;20:521-7.
178. Kulkarni AV, Patwardhan AA, Lele U, Malpathak NP. Production of camptothecin in cultures of Chonemorpha grandiflora. Pharmacognosy Res 2010;2:296-9.
179. Tafur S, Nelson JD, DeLong DC, Svoboda GH. Antiviral components of Ophiorrhiza mungos. Isolation of camptothecin and 10-methoxycamptothecin. Lloydia 1976;39:261-2.
180. Saito K, Sudo H, Yamazaki M, Koseki-Nakamura M, Kitajima M, Takayama H, et al. Feasible production of camptothecin by hairy root culture of Ophiorrhiza pumila. Plant Cell Rep 2011;20:267-71.
181. Asano T, Watase I, Sudo H, Mariko K, Hiromitsu T, Norio A, et al. Camptothecin production by in vitro cultures of Ophiorrhiza liukiuensis and O. kuroiwai. Plant Biotechnol 2004;21:275-81.
182. Kitajima M, Fujii N, Yoshino F, Sudo H, Saito K, Aimi N, et al. Camptothecins and two new monoterpene glucosides from Ophiorrhiza liukiuensis. Chem Pharm Bull (Tokyo) 2005;53:1355-8.
183. Raveendran VV, Jelly CL, Fijesh PV, Padikkala J. Effect of N6-Benzyl amino purine and naphthalene acetic acid on camptothecin production through in vitro propagation of Ophiorrhiza rugosa Wall var decumbens (Gardn ex Thw) Deb and Mondal. Indian J Nat Prod Resources 2007;6:405-9.
184. Gharpure G, Chavan B, Lele U, Hastak A, Bhave A, Malpure N, et al. Camptothecin accumulation in Ophiorrhiza rugosa var prostrata from Northern Western Ghats. Curr Sci 2010;98:302-4.
185. Hamzah AS, Arbain D, Mahyudin, Malviyn VS, Lajis MN. The alkaloids of Ophiorrhiza communis and O. tomentose. Pertanika J Scie Technol 1994;2:33-8.
186. Yi BL, Peng QZ, Tian XR. The research of the camptothecin content in two Ophiorrhiza in Xiang Xi. J Changsha Univ 2007;21:35-6.
187. Rajan R, Varghese SC, Kurup R, Gopalakrishnanc R, Venkataramand R, Satheeshkumarb K, et al. Search for Camptothecin-yielding Ophiorrhiza species from Southern Western ghats in India: A HPTLC-densitometry study. Ind Crops Prod 2013;43:472-6. doi:10. 1016/j. indcrop. 2012. 07. 054.
188. Arbain D, Putra DP, Sargent MV. The alkaloids of Ophiorrhiza filistipula. Aust J Chem 1993;46:977-85.
189. Jain SK, Meena S, Gupta AP, Kushwaha M, Uma Shaanker R, Jaglan S, et al. Dysoxylum binectariferum bark as a new source of anticancer drug camptothecin: Bioactivity-guided isolation and LCMS-based quantification. Bioorg Med Chem Lett 2014;24:3146-9.